Metabolic risk in depression and treatment with selective serotonin reuptake inhibitors: are the metabolic syndrome and an increase in cardiovascular risk unavoidable?

Abstract

Depression is one of the most common psychiatric disorders, and has become an epidemic in modern medical practice; notorious for frequently co-occurring with multiple comorbidities, especially cardiovascular disease (CVD), type 2 diabetes mellitus (DM2), and its various risk factors comprised in the metabolic syndrome (MS). Selective serotonin reuptake inhibitors (SSRIs) are the most widely used class of psychotropic drugs in this and many other clinical scenarios; yet their impact on cardiometabolic health has not been elucidated. The objective of this review was to summarize current views on the pharmacology of SSRIs and cardiometabolic risk, as well as available epidemiological evidence regarding its clinical significance. SSRIs appear to intervene in cardiometabolic physiology fundamentally by modulating chronic inflammation, a key pathophysiologic phenomenon in MS, DM2 and CVD. However, the dosing necessary to achieve a beneficial impact in this regard, as well as their clinical correlations, remain controversial. Each SSRI displays a particular profile regarding each of the components of the MS: weight gain seems to be the most common effect of SSRIs, more frequent with paroxetine, followed by citalopram and escitalopram. As a drug class, SSRIs also appear to promote hypercholesterolemia rather uniformly, while fluoxetine and citalopram appear to particularly increase triacylglyceride levels. In contrast, fluvoxamine and paroxetine seem to have the greatest impact on dysglycemia. Lastly, most SSRIs appear to be innocuous or even beneficial regarding blood pressure and high-density lipoprotein cholesterol. Nevertheless, many of these effects may vary significantly upon specific clinical circumstances, especially timing. This topic remains rather unexplored in clinical psychopharmacology, and further, larger-scale epidemiological studies are needed in order to offer improved care in this field.

Keywords

Depression / selective serotonin reuptake inhibitors / metabolic syndrome / cardiovascular risk / cardiovascular disease / type 2 diabetes mellitus / chronic inflammation

References

[1] Lépine JP.The increasing burden of depression..Neuropsychiatr Dis Treat2011;7:3-7 PMCID:PMC3131101

[2] Reddy MS.Depression: the disorder and the burden..Indian J Psychol Med2010;32:1-2 PMCID:PMC3137804

[3] Hare DL,Johansson P.Depression and cardiovascular disease: a clinical review..Eur Heart J2014;35:1365-72

[4] Colquhoun DM,Clarke DM,Hare DL,Tatoulis J,Tofler GH,Branagan MG.Screening, referral and treatment for depression in patients with coronary heart disease..Med J Aust2013;198:483-4

[5] World Health Organization. Cardiovascular diseases. Media centre fact sheet. Updated May 2017. Available from: http://www.who.int/mediacentre/factsheets/fs317/en/ [Last accessed on 10 Apr 2018]

[6] Forman D.Cardiovascular disease: optimal approaches to risk factor modification of diet and lifestyle..Curr Treat Options Cardiovasc Med2006;8:47-57

[7] Huang PL.A comprehensive definition for metabolic syndrome..Dis Model Mec2009;2:231-7 PMCID:PMC2675814

[8] Olvera RL,Fisher-Hoch SP,McCormick JB.Depression, obesity, and metabolic syndrome: prevalence and risks of comorbidity in a population-based representative sample of Mexican Americans..J Clin Psychiatry2015;76:e1300-5 PMCID:PMC5836315

[9] Kahl KG,Correll C,Busch ML,Schwarz P.Depression, anxiety disorders, and metabolic syndrome in a population at risk for type 2 diabetes mellitus..Brain Behav2015;5:e00306 PMCID:PMC4309892

[10] McIntyre RS,Law CW,Adams A,Lo AK,Woldeyohannes H,Yoon J.The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications..CNS Drugs2010;24:741-53

[11] Chokka P,Yeragani VK.Metabolic syndrome: relevance to antidepressant treatment..J Psychiatry Neurosci2006;31:414 PMCID:PMC1635794

[12] Mitchell AJ,Vancampfort D,De Hert M.Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices..Psychol Med2012;42:125-47

[13] Riordan HJ,Murphy MF.Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and healthcare implications..Am Health Drug Benefits2011;4:292-302 PMCID:PMC4105724

[14] Noordam R,Verhamme KM,Stricker BH.Prescription and indication trends of antidepressant drugs in the Netherlands between 1996 and 2012: a dynamic population-based study..Eur J Clin Pharmacol2015;71:369-75

[15] Tripathi A,Desousa A,Shah N,Grover S,Shinfuku N.Prescription pattern of antidepressants in five tertiary care psychiatric centres of India..Indian J Med Res2016;143:507-13 PMCID:PMC4928559

[16] Santarsieri D.Antidepressant efficacy and side-effect burden: a quick guide for clinicians..Drugs Context2015;4:212290 PMCID:PMC4630974

[17] Chittaranjan A,Sandarsh S.Cardiovascular mechanisms of SSRI drugs and their benefits and risks in ischemic heart disease and heart failure..Int Clin Psychopharmacol2013;28:145-55

[18] Manabe I.Chronic inflammation links cardiovascular, metabolic and renal diseases..Circ J2011;75:2739-48

[19] Berk M,Jacka FN,Pasco JA,Allen NB,Hayley AC,Maes M.So depression is an inflammatory disease, but where does the inflammation come from?.BMC Med2013;11:200 PMCID:PMC3846682

[20] Bica T,Toussaint LL.Depression as a risk factor of organic diseases: an international integrative review..J Nurs Scholarsh2017;49:389-99

[21] Chirinos DA,LeRoy AS.Depressive symptom profiles, cardio-metabolic risk and inflammation: results from the MIDUS study..Psychoneuroendocrinology2017;82:17-25

[22] Mathews MJ,Liebenberg L.The mechanisms by which antidepressants may reduce coronary heart disease risk..BMC Cardiovasc Disord2015;15:82 PMCID:PMC4522054

[23] Maes M,Goehler L,Anderson G,Leonard B.Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways..BMC Med2012;10:66 PMCID:PMC3391987

[24] Cattaneo A,Uher R,Farmer A,Craig IW,Zunsztain PA,Pariante CM.Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'..Neuropsychopharmacology2013;38:377-85 PMCID:PMC3547188

[25] Taler M,Lomnitski L,Baharav E,Zolokov A.Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression..Eur Neuropsychopharmacol2007;17:774-80

[26] Serebruany VL,O'Connor CM.Platelet inhibition by sertraline and n-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors..Pharmacol Res2001;43:453-61

[27] Kubera M,Kenis G,Lasoń W.Effects of serotonin and serotonergic agonists and antagonists on the production of tumor necrosis factor α and interleukin-6..Psychiatry Res2005;134:251-8

[28] Young MR.Serotonin regulation of T-cell subpopulations and of macrophage accessory function..Immunology1995;84:148-52 PMCID:PMC1415171

[29] Hellstrands K.Serotonergic 5-HT1a receptors regulate a cell contact-mediated interaction between natural killer cells and monocytes..Scand J Immunol1993;37:7-18

[30] Nieuwland R,McGregor S,Romijn FP,Hack CE.Cellular origin and procoagulant properties of microparticles in meningococcal sepsis..Blood2000;95:930-5

[31] Shajib M.The role of serotonin and its receptors in activation of immune responses and inflammation..Acta Physiol (Oxf)2014;213:561-74

[32] Rudd ML,Brown BL,Stewart JK.Peritoneal macrophages express the serotonin transporter..J Neuroimmunol2005;159:113-8

[33] de las Casas-Engel M,Sierra-Filardi E,Nieto C,Samaniego R,Corcuera MT,Bustos M,Corbí AL.Serotonin skews human macrophage polarization through HTR2B and HTR7..J Immunol2013;190:2301-10

[34] Biswas SK.Macrophage plasticity and interactionwith lymphocyte subsets: cancer as a paradigm..Nat Immunol2010;11:889-96

[35] Ahern GP.5-HT and the immune system..Curr Opin Pharmacol2011;11:29-33 PMCID:PMC3144148

[36] Kopp S.Blood serotonin and joint pain in seropositive versus seronegative rheumatoid arthritis..Mediators Inflamm2002;11:211-7 PMCID:PMC1781662

[37] Gobin V,Denys D.Selective serotonin reuptake inhibitors as a novel class of immunosuppressants..Int Immunopharmacol2014;20:148-56

[38] Tynan R,Hinwood M,Day T.A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia..Brain Behav Immun2012;26:469-79

[39] St-Onge J,Simoneau J.The stimulation-induced increase in skeletal muscle glycogen synthase content is impaired in carriers of the glycogen synthase XbaI gene polymorphism..Diabetes2001;50:195-8

[40] Levkovitz Y,Hershkovitz A,Gil-Ad I,Ronen D,Zick Y.Antidepressants induce cellular insulin resistance by activation of IRS-1 kinases..Mol Cell Neurosci2007;36:305-12

[41] Goldstein MR,Pezzetta F.Is the increase in LDL cholesterol induced by selective serotonin reuptake inhibitor therapy a blessing in disguise?.Med Hypotheses2010;74:955-6

[42] Avcikurt AS,Kockar F.Antidepressant and antipsychotic drugs differentially affect PON1 enzyme activity..J Enzyme Inhib Med Chem2015;30:245-9

[43] Al-Asmari AK,Al Masoudi AS.Simultaneous administration of fluoxetine and simvastatin ameliorates lipid profile, improves brain level of neurotransmitters, and increases bioavailability of simvastatin..J Exp Pharmacol2017;9:47-57 PMCID:PMC5395284

[44] Roose SP,Kennedy JS,Bigger JTJr,Gaffney A,Finkel MS,Gergel I.Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease..JAMA1998;279:287-91

[45] Kemp AH,Gray MA,Brown K.Impact of depression and antidepressant treatment on heart rate variability: a review and meta-analysis..Biol Psychiatry2010;67:1067-74

[46] Licht CM,Seldenrijk A,Zitman FG,Penninx BW.Depression is associated with decreased blood pressure, but antidepressant use increases the risk for hypertension..Hypertension2009;53:631-8

[47] Serebruany V,Gurbel P.Effect of selective serotonin reuptake inhibitors on platelets in patients with coronary artery disease..Am J Cardiol2001;87:1398-400

[48] Serebruany VL.The relations of major platelet receptor expression during myocardial infarction. Monitoring efficacy of GPIIb/IIIa inhibitors by measuring P-selectin?.Thromb Haemost1999;81:314-6

[49] Andrade C,Chethan K.Serotonin reuptake inhibitor antidepressants and abnormal bleeding..J Clin Psychiatry2010;71:1565-75

[50] Serebruany V.Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something?.Am J Med2006;119:113-6

[51] Musselman D,Manatunga A,Reemsnyder A,Baron A,Nemeroff CB.Platelet reactivity in depressed patients treated with paroxetine..Arch Gen Psychiatry2000;57:875-82

[52] Tseng Y,Huang T,Lane H.A selective serotonin reuptake inhibitor, citalopram, inhibits collagen-induced platelet aggregation and activation..Thromb Res2010;126:517-23

[53] Lekakis J,Papoutsi Z,Nikolaou M,Kremastinos DT.Selective serotonin re-uptake inhibitors decrease the cytokine-induced endothelial adhesion molecule expression, the endothelial adhesiveness to monocytes and the circulating levels of vascular adhesion molecules..Int J Cardiol2010;139:150-8

[54] Herr N,Witsch T,Schmitt S,Bode C.Acute fluoxetine treatment induces slow rolling of leukocytes on endothelium in mice..PLoS One2014;9:e88316 PMCID:PMC3919751

[55] Hiles S,Lamers F,Penninx B.Bidirectional prospective associations of metabolic syndrome components with depression, anxiety, and antidepressant use..Depress Anxiety2016;33:754-64 PMCID:PMC5111740

[56] Shrivastava A.Weight-gain in psychiatric treatment: risks, implications, and strategies for prevention and management..Mens Sana Monogr2010;8:53-68 PMCID:PMC3031940

[57] Ferguson JM.SSRI antidepressant medications: adverse effects and tolerability..Prim Care Companion J Clin Psychiatry2001;3:22-7 PMCID:PMC181155

[58] Raeder M,Vollset S.Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors..J Clin Psychiatry2006;67:1974-82

[59] Serretti A.Antidepressants and body weight..J Clin Psychiatry2010;71:1259-72

[60] McIntyre RS,Law CW,Adams A,Lo AK,Woldeyohannes H,Yoon J.The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications..CNS Drugs2010;24:741-53

[61] Reekie J,Prakash C,Juonala M.The effect of antidepressants and antipsychotics on weight gain in children and adolescents..Obes Rev2015;16:566-80

[62] Wagner KD,Rynn M,Yang R,Childress A,Deas D.Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials..JAMA2003;290:1033-41

[63] Croft H,Houser T,Donahue RM.A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline..Clin Ther1999;21:643-58

[64] de Jonghe F,Tuynman-Qua H.A randomized, double-blind study of fluoxetine and maprotiline in the treatment of major depression..Pharmacopsychiatry1991;24:62-7

[65] Michelson D,Quitkin FM,Rosenbaum JF,Sundell KL,Beasley CMJr.Changes in weight due to a 1-year trial of fluoxetine..Am J Psychiatry1999;156:1170-6

[66] Olguner Eker Ö,Eker B.Metabolic effects of antidepressant treatment..Noro Psikiyatr Ars2017;54:49-56 PMCID:PMC5439472

[67] Fava M,Hoog SL,Koke SC.Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment..J Clin Psychiatry2000;61:863-7

[68] Mansoor B,Hilton R,He J,Emslie GJ,Clarke G,Shamseddeen W,Ryan N.The bidirectional relationship between body mass index and treatment outcome in adolescents with treatment-resistant depression..J Child Adolesc Psychopharmacol2013;23:458-67 PMCID:PMC3779018

[69] Emslie GJ,Hoog SL,Findling RL,Nilsson ME.Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study..J Am Acad Child Adolesc Psychiatry2004;43:1397-405

[70] Nilsson M,Miner C,Heiligenstein J.Safety of subchronic treatment with fluoxetine for major depressive disorder in children and adolescents..J Child Adolesc Psychopharmacol2004;14:412-7

[71] Calarge CA,Janz KF,Coryell WH.Body composition in adolescents during treatment with selective serotonin reuptake inhibitors..Pediatrics2017;140:e20163943

[72] Gibson-Smith D,Milaneschi Y,Visser M,Penninx BW.Major depressive disorder, antidepressant use, and subsequent 2-year weight change patterns in the Netherlands study of depression and anxiety..J Clin Psychiatry2015;77:e144-51

[73] McIntyre R,Konarski J.The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms..Expert Opin Drug Saf2005;5:157-68

[74] Derijks H,Heerdink E,Janknegt R,Egberts AC.The association between antidepressant use and disturbances in glucose homeostasis: evidence from spontaneous reports..Eur J Clin Pharmacol2008;64:531-8 PMCID:PMC2668653

[75] Andersohn F,Suissa S.Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus..Am J Psychiatry2009;166:591-8

[76] Goodnick PJ,Henry JH,Goldberg RB.Sertraline in coexisting major depression and diabetes mellitus..Psychopharmacol Bull1997;33:261-4

[77] Dhavale HS,Jadhav BS,Agari AD.Depression and diabetes: impact of antidepressant medications on glycaemic control..J Assoc Physicians India2013;61:896-9

[78] Maheux P,Bourque J,Chiasson JL.Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss..Int J Obes Relat Metab Disord1997;21:97-102

[79] Kauffman RP,White DL,Owens R.Impact of the selective serotonin reuptake inhibitor citalopram on insulin sensitivity, leptin and basal cortisol secretion in depressed and non-depressed euglycemic women of reproductive age..Gynecol Endocrinol2005;21:129-37

[80] Weber-Hamann B,Lederbogen F,Deuschle M.Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine..J Clin Psychiatry2006;67:1856-61

[81] Paile-Hyvärinen M,Eriksson JG.Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: a single-blind randomised placebo controlled trial..BMC Fam Pract2003;4:7 PMCID:PMC165418

[82] Yoon JM,Lee HK.Antidepressant use and diabetes mellitus risk: a meta-analysis..Korean J Fam Med2013;34:228-40 PMCID:PMC3726790

[83] Yosmaoğlu A,Keyvan A,Erten E,Kora K.Correlation of selective serotonin re-uptake inhibitor use with weight gain and metabolic parameters..Anadolu Psikiyatri Derg2013;14:245-51

[84] Gabriel A.Changes in plasma cholesterol in mood disorder patients: does treatment make a difference?.J Affect Disord2007;99:273-8

[85] Serodio KJ,Rotondi M.Tricyclic and SSRI usage influences the association between BMI and health risk factors..Clin Obes2014;4:296-302

[86] Deisenhammer EA,Liensberger D,Hinterhuber H.No evidence for an association between serum cholesterol and the course of depression and suicidality..Psychiatry Res2004;121:253-61

[87] Ma Y,Pagoto SL,Hebert JR,Goveas JS,Olendzki BC,Smoller JW,Ockene JK,Zorn M.Relations of depressive symptoms and antidepressant use to body mass index and selected biomarkers for diabetes and cardiovascular disease..Am J Public Health2013;103:e34-43 PMCID:PMC3791588

[88] Herran A,Carrera M,Sierra-Biddle D,Ayestarán A,Vázquez-Barquero JL.Panic disorder, treatment with selective serotonin reuptake inhibitors, and cholesterol levels..J Clin Psychopharmacol2006;26:538-40

[89] Wei F,Whitebird RR,O'Connor PJ.Effects of paroxetine and sertraline on low-density lipoprotein cholesterol: an observational cohort study..CNS Drugs2009;23:857-65

[90] Beyazyüz M,Eğilmez OB,Beyazyüz E.Relationship between SSRIs and metabolic syndrome abnormalities in patients with generalized anxiety disorder: a prospective study..Psychiatry Investig2013;10:148-54 PMCID:PMC3687049

[91] Teitelbaum M.Severe hypertriglyceridemia secondary to venlafaxine and fluoxetine..Psychosomatics2001;42:440-1

[92] Teitelbaum M.Severe and moderate hypertriglyceridemia secondary to citalopram and fluoxetine..Psychosomatics2000;41:448-9

[93] Kesim M,Kadioglu M,Kalyoncu NI.The effects of sertraline on blood lipids, glucose, insulin and HBA1C levels: a prospective clinical trial on depressive patients..J Res Med Sci2011;16:1525-31 PMCID:PMC3434892

[94] Khawaja I.Cardiovascular effects of selective serotonin reuptake inhibitors and other novel antidepressants..Heart Dis2003;5:153-60

[95] Pacher P,Nanasi PP,Kecskemeti V.Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any?.Curr Med Chem1999;6:469-80

[96] Nezafati MH,Vojdanparast M,Nezafati P.Selective serotonin reuptake inhibitors and cardiovascular events: a systematic review..J Res Med Sci2016;21:66 PMCID:PMC5122239

[97] Kostev K,Eith T.Which adverse effects influence the dropout rate in selective serotonin reuptake inhibitor (SSRI) treatment? Results for 50,824 patients..Ger Med Sci2014;12:Doc15 PMCID:PMC4202666

[98] Katsi VK,Vamvakou G,Tousoulis D,Vardas P.Novel antidepressant drugs, arterial hypertension and cardiovascular disease..Recent Pat Cardiovasc Drug Discov2013;8:178-85

[99] Fjukstad KK,Lydersen S,Steen NE,Spigset O.Metabolic abnormalities related to treatment with selective serotonin reuptake inhibitors in patients with schizophrenia or bipolar disorder..J Clin Psychopharmacol2016;36:615-20 PMCID:PMC5098465

[100] Licht C,Geus E.Effects of antidepressants, but not psychopathology, on cardiac sympathetic control: a longitudinal study..Neuropsychopharmacology2012;37:2487-95 PMCID:PMC3442343

[101] Hinze-Selch D,Kraus T,Uhr M,Pollmächer T.Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: a longitudinal study in patients treated with amitriptyline or paroxetine..Neuropsychopharmacology2000;23:13-9

[102] Weber E,Pollock BG,Begley A,Reynolds CF3rd.Weight change in older depressed patients during acute pharmacotherapy with paroxetine and nortriptyline: a double-blind randomized trial..Am J Geriatr Psychiatry2000;8:245-50

[103] Nemeroff CB,Gyulai L,Bowden CL,Oakes R.Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression..Am J Psychiatry2001;158:906-12

[104] Paile-Hyvärinen M,Eriksson JG.Quality of life and metabolic status in mildly depressed patients with type 2 diabetes treated with paroxetine: a double-blind randomised placebo controlled 6-month trial..BMC Fam Pract2007;8:34 PMCID:PMC1914073

[105] Ye Z,Yang Z,Huang Y,Zhang S,Wang X,Hu J,Qu S.Metabolic effects of fluoxetine in adults with type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials..PLoS One2011;6:e21551 PMCID:PMC3145630

[106] O'Kane M,Wales JK.Fluoxetine in the treatment of obese type 2 diabetic patients..Diabet Med1994;11:105-10

[107] Breum L,Bak JF,Astrup A.Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity..Metabolism1995;44:1570-6

[108] Fava M.Weight gain and antidepressants..J Clin Psychiatry2000;61:37-41

[109] Moon CA.The effects of psychomotor performance of fluvoxamine versus mianserin in depressed patients in general practice..Br J Clin Pract1991;45:259-62

[110] Nihalani N,Siddiqui UA.Weight gain, obesity, and psychotropic prescribing..J Obes2011;2011:893629 PMCID:PMC3034985

[111] Aberg-Wistedt A,Ekselius L,Akerblad AC.Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy..J Clin Psychopharmacol2000;20:645-52

[112] Bouwer CD.Phasic craving for carbohydrate observed with citalopram..Int Clin Psychopharmacol1996;11:273-8

[113] Emslie GJ,Korotzer A.Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial..J Am Acad Child Adolesc Psychiatry2009;48:721-9

[114] Pigott TA,Arnold LM,Mallinckrodt CH.Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder..Curr Med Res Opin2007;23:1303-18